Vaccine antigens adsorbed to aluminum phosphate adjuvant (AlPO4-adsorbed antigens)

Vaccine antigens adsorbed to aluminum phosphate adjuvant represent a specialized immunological formulation designed to enhance the body's immune response to specific pathogens. Aluminum phosphate (AlPO4) acts as an adjuvant by physically binding to vaccine antigens, which creates a depot at the injection site for the slow, sustained release of the immunogen (Marrack et al., 2009). This mechanism ensures prolonged exposure of the antigen to the immune system, facilitating the recruitment and activation of professional antigen-presenting cells like dendritic cells and macrophages (Ghimire, 2015). Furthermore, aluminum phosphate is known to activate the NLRP3 inflammasome, which promotes the secretion of pro-inflammatory cytokines and biases the immune response toward a T-helper 2 (Th2) profile (Kool et al., 2008). This Th2 bias is particularly effective for stimulating the production of high-affinity neutralizing antibodies, which are crucial for protection against bacterial toxins and viral infections (Petrovsky & Aguilar, 2004). These adjuvanted complexes are foundational components of many widely used vaccines, including those for Hepatitis A, Diphtheria, Tetanus, and Pertussis (CDC, 2020). While highly effective, the use of these complexes is associated with localized safety concerns such as injection site redness, swelling, and the rare formation of granulomas (StatPearls, 2023).

Other names

Aluminum phosphate-adsorbed vaccineAlPO4 adjuvant-antigen complexAdjuvanted vaccine antigensAluminum phosphate-precipitated antigens

Enhancement of immune response via depot effect, recruitment of antigen-presenting cells, and activation of the NLRP3 inflammasome to promote a Th2-biased antibody response.